amlodipine besylate - Profile

What are the generic drug sources for amlodipine besylate and what is the scope of patent protection?

Amlodipine besylate is the generic ingredient in twenty-one branded drugs marketed by Brillian Pharma, Cmp Dev Llc, Synthon Pharms, Accord Hlthcare, Alkem, Amneal Pharms Ny, Aurobindo Pharma, Chartwell Rx, China Resources, Cipla, Corepharma, Epic Pharma Llc, Gedeon Richter Usa, Genpharm, Graviti Pharms, Hikma, Hikma Pharms, Invagen Pharms, Lupin, Mylan, Orbion Pharms, Oxford Pharms, Pharmobedient, Puracap Labs Blu, Puracap Pharm, Sciegen Pharms, Sovereign Pharms, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Sun Pharm Industries, Sunshine, Teva, Teva Pharms Inc, Torrent Pharms, Unichem, Watson Labs, Wockhardt, Zydus Pharms Usa, Viatris, Alembic, Apotex, Dr Reddys, Neocubes Pharma, Pharmacia, Amneal, Aurobindo Pharma Ltd, Dr Reddys Labs Inc, Heritage, Lupin Pharms, Rising, Teva Pharms, Watson Labs Inc, Sandoz, Purple Biotech, Hetero Labs Ltd V, Macleods Pharms Ltd, Micro Labs, Ph Health, Piramal, Teva Pharms Usa, Torrent, Cosette, Lupin Ltd, Strides Pharma Intl, Novartis, Azurity, Accord Hlthcare Inc, Ajanta Pharma Ltd, Alkem Labs Ltd, Glenmark Pharms Ltd, Jubilant Generics, Zydus Pharms, Adhera, Boehringer Ingelheim, Hetero Labs, and Novel Labs Inc, and is included in one hundred and eleven NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are three tentative approvals for this compound.

Summary for amlodipine besylate

US Patents:	11
Tradenames:	21
Applicants:	77
NDAs:	111
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for amlodipine besylate

Generic filers with tentative approvals for AMLODIPINE BESYLATE

Applicant	Application No.	Strength	Dosage Form
		EQ 10MG BASE	TABLET;ORAL
		EQ 5MG BASE	TABLET;ORAL
		EQ 2.5MG BASE	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for amlodipine besylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Brillian Pharma	SDAMLO	amlodipine besylate	FOR SOLUTION;ORAL	219531-001	Jul 24, 2025		RX	Yes	Yes
Brillian Pharma	SDAMLO	amlodipine besylate	FOR SOLUTION;ORAL	219531-002	Jul 24, 2025		RX	Yes	Yes
Brillian Pharma	SDAMLO	amlodipine besylate	FOR SOLUTION;ORAL	219531-003	Jul 24, 2025		RX	Yes	Yes
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	12,226,528		Y
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	11,458,095		Y
Cmp Dev Llc	NORLIQVA	amlodipine besylate	SOLUTION;ORAL	214439-001	Feb 24, 2022		RX	Yes	Yes	12,005,141		Y

Expired US Patents for amlodipine besylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Synthon Pharms	AMLODIPINE BESYLATE	amlodipine besylate	TABLET, ORALLY DISINTEGRATING;ORAL	022026-003	Sep 27, 2007	6,828,339
Synthon Pharms	AMLODIPINE BESYLATE	amlodipine besylate	TABLET, ORALLY DISINTEGRATING;ORAL	022026-001	Sep 27, 2007	6,828,339
Synthon Pharms	AMLODIPINE BESYLATE	amlodipine besylate	TABLET, ORALLY DISINTEGRATING;ORAL	022026-002	Sep 27, 2007	6,828,339

Amlodipine Besylate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Amlodipine besylate, a calcium channel blocker primarily used to treat hypertension and angina pectoris, presents a significant investment opportunity driven by global cardiovascular disease prevalence, evolving regulatory landscapes, and patent expirations. The drug’s market has shown resilience, with an annual compound growth rate approximating 3-5% in recent years. The upcoming biosimilar and generic entrants post-patent expiry are predicted to influence revenue streams, while ongoing research into combination therapies and new indications may provide additional revenue avenues. This analysis offers a comprehensive view of the market landscape, investment potential, and financial forecasts for amlodipine besylate.

---

Market Overview and Dynamics

Global Market Size and Growth

Year	Market Size (USD Billion)	Growth Rate	Key Drivers
2021	3.2	N/A	Increasing hypertension prevalence, aging populations, improved diagnosis
2022	3.4	+6.3%	Rising awareness, expanding healthcare infrastructure
2023 (Estimated)	3.5	+3.7%	Market saturation in some regions, patent protections in others

Source: [1], [2]

Regional Market Breakdown

Region	Revenue Share (%)	CAGR (2022-2027)	Key Factors
North America	45	3.2%	High adoption rates, strong healthcare systems
Europe	25	2.8%	Aging population, regulatory environment
Asia Pacific	20	5.0%	Large patient pool, emerging economies
Rest of World	10	4.2%	Increasing healthcare access

Key Market Drivers

• Rising Prevalence of Hypertension: Approximately 1.28 billion adults globally, projected to increase [3].
• Patent Expirations: Major patents scheduled to expire between 2023-2028, opening markets for generics.
• Healthcare Access and Infrastructure: Expansion in emerging markets.
• Combination Therapies: Development of fixed-dose combinations enhancing adherence.

Market Constraints

• Generic Competition: Post-patent expiry, multiple entrants lead to price erosion.
• Regulatory Hurdles: Stringent approval processes, especially in key markets.
• Reimbursement Policies: Variability across regions affecting access and sales.

---

Patent Landscape and Regulatory Environment

Patent Expiry Timeline

Patent Holder	Patent Expiration	Market Impact	Notes
Pfizer (original patent)	2023	Significant generic entry expected	Patent cliff impact hypertension drug market [4]
Patent extensions (if any)	2024-2028	Potential delays	Pending lawsuits or patent challenges

Regulatory Approvals and Quality Standards

• FDA (USA): Approved as a prescription drug for hypertension and angina.
• EMA (Europe): Similar approval status.
• Emerging Markets: Faster approvals but varied standards; increasing reliance on WHO prequalification for generics.

---

Financial Trajectory and Investment Opportunities

Revenue Forecasts

Scenario	Year	Revenue (USD Million)	Assumptions
Base Case	2023	500	Post-patent expiry, moderate generic penetration
Optimistic	2025	600	Growing adoption, combination formulations market expansion
Pessimistic	2024	400	Price erosion, slower market growth

Note: Revenue projections incorporate market penetration rates, pricing trends, and regulatory developments.

Profitability Outlook

Metric	2021	2025 (Projected)	Notes
Gross Margin	60%	55-60%	Impact of generic pricing
R&D Spending	2-4% of sales	Maintained	Focus on combination therapies or new indications

Investment Considerations

• Generic and Biosimilar Companies: Potential acquisition or licensing opportunities.
• Pharmaceutical Firms: Strategic partnerships for combination formulations.
• Emerging Markets: Expansion strategies for low-penetration regions.

---

Competitive Landscape

Major Players	Market Share (%)	Key Strategies	Notable Product Variations
Pfizer	50	Patent protections, brand loyalty	Norvasc
Mylan	15	Generic manufacturing	Amlodipine Besylate (Generic)
Teva	10	Cost leadership	Amlodipine & Hydrochlorothiazide combo
Others	25	Regional players, biosimilars	Various

---

Future Market and R&D Trends

Emerging Indications and Combinations

• Combination therapies: Amlodipine with ACE inhibitors, diuretics, or statins.
• New formulations: Extended-release, malleable dosage forms.
• Novel indications: Investigational research into targeted hypertension subpopulations.

Innovation Drivers

• Advances in drug delivery systems.
• Personalized medicine approaches.
• Digital health integration for compliance and monitoring.

---

Comparative Analysis with Similar Drugs

Drug	Primary Use	Patent Status	Market CAGR	Key Differentiators
Amlodipine	Hypertension	Expired (2023)	3-5%	Well-characterized, low cost
Lisinopril	Hypertension	Patents expired	2-4%	ACE inhibitor, alternative class
Diltiazem	Angina, Hypertension	Active patents	2-3%	Additional indications

---

FAQs

What are the primary growth drivers for amlodipine besylate?

Increasing global hypertension prevalence, aging populations, healthcare infrastructure expansion, and the development of combination therapies are key drivers.

How will patent expirations affect the market?

Post-2023, significant generic entry is expected, leading to price competition, revenue decline for brand formulations, but new product formulations and combination therapies could sustain growth.

Which regions offer the most promising investment opportunities?

Asia Pacific offers high growth potential due to large patient populations and emerging markets. North America and Europe remain stable, premium markets with high reimbursement rates.

Are there ongoing research areas that could impact market size?

Yes, research into fixed-dose combinations, extended-release formulations, and new indications might open new revenue streams and prolong market relevance.

What are the risks associated with investing in amlodipine besylate?

Price erosion following patent expiry, regulatory complexities, competitive generic markets, and healthcare reimbursement policies pose risks. Diversification into combination therapies and biosimilars mitigates some market risks.

---

Key Takeaways

• Market Maturity: Amlodipine besylate is a mature drug facing patent expiration, with immediate opportunities for generics and biosimilars.
• Growth Potential: Long-term growth remains driven by global hypertension burden and innovation in combination therapies.
• Competitive Dynamics: The landscape will shift post-patent expiry, emphasizing cost leadership and formulation innovation.
• Regional Variability: Asia-Pacific presents high-growth prospects; developed markets offer stable revenue streams.
• Strategic Focus: Investment in R&D, strategic partnerships, and entry into emerging markets are recommended for diversified growth.

---

References

[1] GlobalData, “Cardiovascular Drugs Market Analysis 2021,” 2022.
[2] IQVIA, “Prescription Drug Market Trends,” 2022.
[3] World Health Organization, “Hypertension Prevalence Data,” 2021.
[4] U.S. Patent and Trademark Office, “Patent Expirations in the Hypertension Drug Sector,” 2023.